In addition to directly influencing the variables of GV, dapagliflozin as an adjuvant therapy to basal insulin also exhibited a significant decrease in fluctuations of blood glucose in Japanese patients with T2DM [114]. This evidence concerns the gene INS and type 2 diabetes mellitus.